# Korro Bio

Type: Company (KRRO)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/korro-bio
Canonical HTML page: https://gethealthbrief.com/entity/korro-bio

## Timeline

- **2027**: Pipeline Expansion — Expected utilization of funds to advance additional candidates from the OPERA platform.
- **2026-Q3**: Clinical Milestone Expected — Anticipated progress updates on the KRRO-110 Phase 1/2 clinical trial for AATD.
- **2026-03-09**: Private Placement Announced — Korro Bio announces the closing of an $85 million oversubscribed private placement.

## Recent coverage (1 stories)

### Korro Bio Secures $85M in Oversubscribed Private Placement for RNA Editing
2026-03-09 12:49:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Korro Bio (NASDAQ: KRRO) has successfully closed an $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. The capital infusion is earmarked for the clinical advancement of its lead candidate, KRRO-110, and the expansion of its OPERA platform.
Full story: https://gethealthbrief.com/story/korro-bio-85m-private-placement-rna-editing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.